Discounted Cash Flow Rating

Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Sell

C

Molecular Partners AG American Depositary Shares (MOLN)

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/16/2021

Market Cap

210,011,799

Shares Outstanding

36,350,000

Weighted SO

32,854,297

Total Employees

N/A

Upcoming Earnings

08/28/2024

Similar Tickers

MLYS --.--%

ANTX --.--%

PHVS --.--%

PEPG --.--%

MNOV --.--%

ANEB --.--%

CSBR --.--%

CYT --.--%

RZLT --.--%

Beta

0.6520

Last Div

0.0000

Range

3.32-12.7

Chg

0.1868

Avg Vol

39046

Mkt Cap

210011799

Exch

NASDAQ

Country

CH

Phone

41 44 755 77 00

DCF Diff

1.4777

DCF

4.8491

Div Yield

0.0000

P/S

27.0995

EV Multiple

-0.2009

P/FV

1.0708

Div Yield %

0.0000

P/E

-3.0836

PEG

0.0203

Payout

0.0000

Current Ratio

14.6755

Quick Ratio

14.6755

Cash Ratio

14.1825

DSO

172.5149

DIO

0.0000

Op Cycle

172.5149

DPO

23.7810

CCC

148.7339

Gross Margin

-6.3228

Op Margin

-9.1998

Pretax Margin

-8.7022

Net Margin

-8.7022

Eff Tax Rate

-0.0194

ROA

-0.3154

ROE

-0.3134

ROCE

-0.3570

NI/EBT

1.0000

EBT/EBIT

0.9459

EBIT/Rev

-9.1998

Debt Ratio

0.0181

D/E

0.0199

LT Debt/Cap

0.0125

Total Debt/Cap

0.0195

Int Coverage

-1767.9429

CF/Debt

-17.0472

Equity Multi

1.1012

Rec Turnover

2.1158

Pay Turnover

15.3484

Inv Turnover

0.0000

FA Turnover

1.2802

Asset Turnover

0.0362

OCF/Share

-1.7380

FCF/Share

-1.7617

Cash/Share

8.5163

OCF/Sales

-8.4932

FCF/OCF

1.0136

CF Coverage

-17.0472

ST Coverage

-47.2107

CapEx Coverage

-73.3312

Div&CapEx Cov

-73.3312

P/BV

1.0708

P/B

1.0708

P/S

27.0995

P/E

-3.0836

P/FCF

-3.1478

P/OCF

-3.1595

P/CF

-3.1595

PEG

0.0203

P/S

27.0995

EV Multiple

-0.2009

P/FV

1.0708

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Feb 28, 06:00 Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call GlobeNewswire Inc. Jan 12, 18:00 Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Jan 12, 18:00 Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer GlobeNewswire Inc. Jun 17, 05:00 Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit GlobeNewswire Inc. Jun 14, 05:00 Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024 GlobeNewswire Inc. Jun 11, 05:00 Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024 GlobeNewswire Inc. Jan 07, 16:00 Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Jan 07, 16:00 Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Jan 07, 16:00 Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Jan 07, 16:00 Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Jan 07, 16:00 Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Jan 07, 16:00 Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Jan 07, 16:00 Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Jan 07, 16:00 Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Jan 07, 16:00 Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Jan 07, 16:00 Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Jan 07, 16:00 Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Dec 14, 01:00 Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences GlobeNewswire Inc. Dec 14, 01:00 Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences GlobeNewswire Inc. Dec 14, 01:00 Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences

Revenue Product Segmentation